Kaplan-Meier estimates of DFS in AML patients categorized according to 2017 ELN genetic risk classification by treatment arm. Patients receiving G3139 (arm A) and those in the control arm (arm B) were arranged into 3 genetic risk groups (favorable, intermediate, or adverse) based on their cytogenetic and molecular genetic findings at diagnosis.¹⁸